CTOs on the Move

20/20 GeneSystems Inc

www.2020gene.com

 
20/20 GeneSystems Inc is a Rockville, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million
  • www.2020gene.com
  • 9430 Key West Ave
    Rockville, MD USA 20850
  • Phone: 240.453.6339

Executives

Name Title Contact Details

Similar Companies

Synaptogenix

Synaptogenix is a clinical-stage biotech company leveraging Bryostatin-1 and its analogues to discover and develop targeted therapeutics for neurodegenerative diseases and developmental disorders.

ProteoCell Biotechnologies

ProteoCell Biotechnologies Inc. is a Laval, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Scioto Biosciences

Scioto Biosciences is a preclinical stage biotech company dedicated to innovative research and discovery in the field of microbiome therapeutics.

Q Bio

Our Q Exam is based on landmark systems biology research done at Stanford University. In about 75 minutes, we take blood, saliva, urine and a non-invasive whole-body scan from which we measure over 3000 clinically-relevant genetic, chemical, and anatomical biomarkers to build the world`s most comprehensive quantitative snapshot of your health at a point in time.

Adagio Therapeutics

Adagio Therapeutics, Inc` is a clinical-stage a biotechnology company developing best-in-class antibodies that can broadly neutralize SARS-CoV-2, SARS-CoV-1 and additional pre-emergent coronaviruses` Our candidates are optimized using Adimab’s industry-leading antibody engineering capabilities and are designed to provide patients and clinicians with an unsurpassed combination of potency, breadth, durable protection (via half-life extension), manufacturability, tolerability, and affordability` Our portfolio of SARS-CoV-2 antibodies includes multiple, non-competing antibodies with distinct binding epitopes` Pre-clinical data show that our lead antibody ADG20 matches or exceeds the potency and coverage of other clinical SARS-CoV-2 antibody programs` We plan to advance ADG20 aggressively through global clinical trials for both the prevention and treatment of symptomatic COVID-19 and anticipate data from both prevention and treatment clinical trials in 2021` Adagio has secured manufacturing capacity for the production of ADG20 with third party contract manufacturers through the completion of clinical trials and, if approved by regulatory authorities, through initial commercial launch`